Real‐Time Individual Predictions of Prostate Cancer Recurrence Using Joint Models

Patients who were previously treated for prostate cancer with radiation therapy are monitored at regular intervals using a laboratory test called Prostate Specific Antigen (PSA). If the value of the PSA test starts to rise, this is an indication that the prostate cancer is more likely to recur, and the patient may wish to initiate new treatments. Such patients could be helped in making medical decisions by an accurate estimate of the probability of recurrence of the cancer in the next few years. In this article, we describe the methodology for giving the probability of recurrence for a new patient, as implemented on a web-based calculator. The methods use a joint longitudinal survival model. The model is developed on a training dataset of 2386 patients and tested on a dataset of 846 patients. Bayesian estimation methods are used with one Markov chain Monte Carlo (MCMC) algorithm developed for estimation of the parameters from the training dataset and a second quick MCMC developed for prediction of the risk of recurrence that uses the longitudinal PSA measures from a new patient.

[1]  Menggang Yu,et al.  Individual Prediction in Prostate Cancer Studies Using a Joint Longitudinal Survival–Cure Model , 2008 .

[2]  Paul Schellhammer,et al.  Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference. , 2006, International journal of radiation oncology, biology, physics.

[3]  Cécile Proust-Lima,et al.  Determinants of change in prostate-specific antigen over time and its association with recurrence after external beam radiation therapy for prostate cancer in five large cohorts. , 2008, International journal of radiation oncology, biology, physics.

[4]  Yan Wang,et al.  Jointly Modeling Longitudinal and Event Time Data With Application to Acquired Immunodeficiency Syndrome , 2001 .

[5]  D. Ankerst,et al.  Clinical monitoring based on joint models for longitudinal biomarkers and event times , 2006 .

[6]  Douglas E Schaubel,et al.  The effect of salvage therapy on survival in a longitudinal study with treatment by indication , 2010, Statistics in medicine.

[7]  S. Zeger,et al.  Joint analysis of longitudinal data comprising repeated measures and times to events , 2001 .

[8]  Jeremy MG Taylor,et al.  Validation of Biomarker-Based Risk Prediction Models , 2008, Clinical Cancer Research.

[9]  R Henderson,et al.  Joint modelling of longitudinal measurements and event time data. , 2000, Biostatistics.

[10]  C. McCulloch,et al.  Latent Class Models for Joint Analysis of Longitudinal Biomarker and Event Process Data , 2002 .

[11]  Menggang Yu,et al.  Individualized Predictions of Disease Progression Following Radiation Therapy for Prostate Cancer , 2005 .

[12]  Scott Tyldesley,et al.  Evaluation of the Houston biochemical relapse definition in men treated with prolonged neoadjuvant and adjuvant androgen ablation and assessment of follow-up lead-time bias. , 2003, International journal of radiation oncology, biology, physics.

[13]  Cécile Proust-Lima,et al.  Joint latent class models for longitudinal and time-to-event data: A review , 2014, Statistical methods in medical research.

[14]  Menggang Yu,et al.  JOINT LONGITUDINAL-SURVIVAL-CURE MODELS AND THEIR APPLICATION TO PROSTATE CANCER , 2004 .

[15]  N. Obuchowski,et al.  Assessing the Performance of Prediction Models: A Framework for Traditional and Novel Measures , 2010, Epidemiology.

[16]  Cécile Proust-Lima,et al.  Development and validation of a dynamic prognostic tool for prostate cancer recurrence using repeated measures of posttreatment PSA: a joint modeling approach. , 2009, Biostatistics.

[17]  Dimitris Rizopoulos,et al.  Dynamic Predictions and Prospective Accuracy in Joint Models for Longitudinal and Time‐to‐Event Data , 2011, Biometrics.